Ocular

OCUL NASDAQ
4.430
-0.260
-5.54%
盘后: 4.430 0 0.00% 16:00 08/23 EDT
开盘
4.690
昨收
4.690
最高
4.850
最低
4.410
成交量
72.25万
成交均量(3M)
88.36万
52周最高
7.31
52周最低
2.350
换手率
1.53%
市值
2.09亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Ocular OCUL股票价格,Ocular股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
展开 >

最近浏览

名称
价格
涨跌幅